title: An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation.
abstract: The study of breast cancer dormancy in the bone marrow is an exceptionally difficult undertaking due to the complexity of the interactions of dormant cells with their microenvironment, their rarity and the overwhelming excess of hematopoietic cells. Towards this end, we developed an in vitro 2D clonogenic model of dormancy of estrogen-sensitive breast cancer cells in the bone marrow. The model consists of a few key elements necessary for dormancy. These include 1) the use of estrogen sensitive breast cancer cells, which are the type likely to remain dormant for extended periods, 2) incubation of cells at clonogenic density, where the structural interaction of each cell is primarily with the substratum, 3) fibronectin, a key structural element of the marrow and 4) FGF-2, a growth factor abundantly synthesized by bone marrow stromal cells and heavily deposited in the extracellular matrix. Cells incubated with FGF-2 form dormant clones after 6 days, which consist of 12 or less cells that have a distinct flat appearance, are significantly larger and more spread out than growing cells and have large cytoplasm to nucleus ratios. In contrast, cells incubated without FGF-2 form primarily growing colonies consisting of>30 relatively small cells. Perturbations of the system with antibodies, inhibitors, peptides or nucleic acids on day 3 after incubation can significantly affect various phenotypic and molecular aspects of the dormant cells at 6 days and can be used to assess the roles of membrane-localized or intracellular molecules, factors or signaling pathways on the dormant state or survival of dormant cells. While recognizing the in vitro nature of the assay, it can function as a highly useful tool to glean significant information about the molecular mechanisms necessary for establishment and survival of dormant cells. This data can be used to generate hypotheses to be tested in vivo models.
authors.affiliation: Department of Medicine and New Jersey Medical School Cancer Center, Rutgers New Jersey Medical School.
authors.forename: Samir
authors.initials: S
authors.lastname: Tivari
authors.affiliation: Department of Medicine and New Jersey Medical School Cancer Center, Rutgers New Jersey Medical School.
authors.forename: Reju
authors.initials: R
authors.lastname: Korah
authors.affiliation: Department of Medicine and New Jersey Medical School Cancer Center, Rutgers New Jersey Medical School.
authors.forename: Michael
authors.initials: M
authors.lastname: Lindy
authors.affiliation: Department of Medicine and New Jersey Medical School Cancer Center, Rutgers New Jersey Medical School; wiederro@njms.rutgers.edu.
authors.forename: Robert
authors.initials: R
authors.lastname: Wieder
mesh_terms: D019046:Bone Marrow Neoplasms / Q000378:metabolism* / Q000473:pathology*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism* / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism*; D054460:rho-Associated Kinases / Q000378:metabolism
chemical_list: D011960:Receptors, Estrogen; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D054460:rho-Associated Kinases